United Health Products is making strategic moves to bring its hemostatic agent CelluSTAT to market, focusing on regulatory compliance and capital acquisition. The company has submitted an application to OTC Markets for OTCQB market quotation and is actively pursuing FDA approval through a comprehensive Premarket Approval (PMA) process.
The company has successfully raised over $500,000 through private placement transactions, avoiding reliance on its existing Equity Line of Credit. These funds will support ongoing clinical activities required for the PMA application. UHP has submitted an Investigational Device Exemption (IDE) application to the FDA and is preparing for clinical trials at three facilities within a national hospital network.
In response to FDA requirements, UHP is completing additional sterilization and biotoxicity tests, expected to be submitted by the end of March. This will enable the FDA to conduct its final review of the IDE application. The company has negotiated a Clinical Trial Agreement to facilitate the 27 surgical procedures requested by regulatory authorities.
Despite potential workforce changes within federal agencies, UHP reports that FDA response times remain consistent with previous interactions. The company remains committed to obtaining necessary approvals for CelluSTAT, a natural hemostatic agent designed to control mild to moderate bleeding in surgical settings.
While the company acknowledges uncertainties in the approval process, its methodical approach demonstrates a strategic commitment to bringing its medical technology to market. Investors and medical professionals will be watching closely as UHP continues to navigate regulatory and capital market challenges.
